Tuesday, July 1, 2025 7/1/2025

Furopyrimidines as novel inhibitors of henipaviruses

Award Number: R41AI157095
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/11/2021
PERIOD OF PERFORMANCE END DATE: 12/31/2023

Group Awards By:

View Award Description

Furopyrimidines as novel inhibitors of henipaviruses - The emergence and reemergence of pathogenic viruses represent continuous infectious disease threats to public health. Among these, the paramyxoviruses, which include many important human and animal pathogens, also include two excellent examples of emerged, zoonotic viral pathogens of importance: the henipaviruses; Hendra virus (HeV) and Nipah virus (NiV). HeV and NiV have a uniquely broad host tropism capable of infecting at least 18 animal species across 6 orders of mammals. HeV and NiV can also cause a systemic and often fatal respiratory and/or neurological disease in 11 mammalian species including humans. These henipaviruses remain significant biothreats to humans and economically important livestock in Australia and throughout South East Asia. In addition, there are no vaccines or antivirals approved for human use. Thus new treatment options are urgently needed. This application defines a plan to develop potent, small molecule inhibitors, which inhibit henipavirus replication. We have identified compounds that inhibit replication of these viruses, with IC50 values in the nanomolar range. In this application, we propose three specific aims: (1) To optimize the lead (and backup) scaffold and select developmental candidates; (2) Develop the SAR in the henipavirus infectious assay and further investigate the mechanism of action (MOA) of the replication inhibitors; and (3) Select henipavirus inhibitors with in vitro ADME properties suitable for whole animal testing in an infectious animal model.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	CHICAGO BIOSOLUTIONS INC	2242 W HARRISON ST	CHICAGO	IL	60612	COOK	USA	Allergy and Infectious Diseases Research	000	2	8/1/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $299,667 )
2022	2022	CHICAGO BIOSOLUTIONS, INC.	2242 WEST HARRISON SUITE 201	CHICAGO	IL	60612	COOK	USA	Allergy and Infectious Diseases Research	000	2	2/14/2022	NON-COMPETING CONTINUATION	$299,667
														Subtotal = $299,667

Issue Date FY: 2021 ( Subtotal = $299,595 )
2021	2021	CHICAGO BIOSOLUTIONS, INC.	2242 WEST HARRISON SUITE 201	CHICAGO	IL	60612	COOK	USA	Allergy and Infectious Diseases Research	000	1	1/11/2021	NEW	$299,595
														Subtotal = $299,595

Grand Total All Awards = $599,262

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Furopyrimidines as novel inhibitors of henipaviruses

Award Number: R41AI157095

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/11/2021

PERIOD OF PERFORMANCE END DATE: 12/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer